Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included adult PsO patients enrolled in the Corrona Psoriasis Registry who initiated ixekizumab, TNFi, or other IL‐17i between...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Dermatol Ther
Main Authors: Lockshin, Benjamin, Cronin, Angel, Harrison, Ryan W., McLean, Robert R., Anatale‐Tardiff, Laura, Burge, Russel, Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Gallo, Gaia, Strober, Bruce, Van Voorhees, Abby
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047872/
https://ncbi.nlm.nih.gov/pubmed/33491259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.14808
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados